Mathias Falcenberg, PhD
Mathias is Associate and is located in the Munich Office where he supports the evaluation of investment opportunities and due diligence processes.
Mathias joined Forbion in 2016. Before, he was project leader for metabolic disease therapy at the Max Planck Institute of Biochemistry (MPIB), managing international and multi-disciplinary drug discovery collaborations as well as supervising a research team to investigate GRK5 signaling in diabetes and cancer. Based on his scientific findings, which led to four patents, he gained a seed financing by GlaxoSmithKline and managed the scientific implementation of this joint venture on behalf of the MPIB. Supported by Prof. Dr. Axel Ullrich, the generated data provided the basis of spin-out activities within the field of type 2 diabetes, which Mathias accompanied as co-founder and CSO.
Mathias received his PhD from the Max-Planck-Institute of Biochemistry in Prof. Dr. Axel Ullrichs department, investigating sutent-sensitive kinases as targets for novel anti-diabetic therapy development.